A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”

Схожі ресурси

• A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”
  за авторством: Sonja Ständer, та інші
  Опубліковано: (2025-12-01)
• Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’
  за авторством: Mike Bastian, та інші
  Опубліковано: (2024-02-01)
• Letter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison”
  за авторством: Raj Chovatiya, та інші
  Опубліковано: (2025-12-01)
• Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
  за авторством: Kim Rand, та інші
  Опубліковано: (2023-10-01)
• Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison
  за авторством: Surya P. Bhatt, та інші
  Опубліковано: (2025-09-01)